These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 32026157)

  • 1. Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.
    Mytsyk Y; Pasichnyk S; Dutka I; Dats I; Vorobets D; Skrzypczyk M; Uteuliyev Y; Botikova A; Gazdikova K; Kubatka P; Urdzik P; Kruzliak P
    Clin Exp Med; 2020 May; 20(2):277-287. PubMed ID: 32026157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
    Beuselinck B; Pans S; Bielen J; De Wever L; Noppe N; Vanderschueren G; De Keyzer F; Baldewijns M; Lerut E; Laenen A; Verbiest A; Roussel E; Albersen M; Vandecaveye V
    Acta Oncol; 2020 Jul; 59(7):818-824. PubMed ID: 32297532
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
    McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
    Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
    Krajewski KM; Franchetti Y; Nishino M; Fay AP; Ramaiya N; Van den Abbeele AD; Choueiri TK
    Oncologist; 2014 May; 19(5):507-14. PubMed ID: 24755461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
    Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
    Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
    Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
    AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies.
    Schmidt N; Hess V; Zumbrunn T; Rothermundt C; Bongartz G; Potthast S
    Eur Radiol; 2013 Mar; 23(3):632-9. PubMed ID: 22918564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
    Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
    Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
    Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
    Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
    Kelly-Morland C; Rudman S; Nathan P; Mallett S; Montana G; Cook G; Goh V
    BMC Cancer; 2017 Jun; 17(1):392. PubMed ID: 28578690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
    Erman M; Biswas B; Danchaivijitr P; Chen L; Wong YF; Hashem T; Lim CS; Karabulut B; Chung HJ; Chikatapu C; Ingles S; Slimane K; Kanesvaran R
    BMC Cancer; 2021 Sep; 21(1):1021. PubMed ID: 34521387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC).
    Gupta S; Kang HC; Sun J; Matrana MR; Tannir NM; Choi H
    Abdom Radiol (NY); 2020 Jun; 45(6):1872-1882. PubMed ID: 31822966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can diffusion-weighted magnetic resonance imaging of clear cell renal carcinoma predict low from high nuclear grade tumors.
    Parada Villavicencio C; Mc Carthy RJ; Miller FH
    Abdom Radiol (NY); 2017 Apr; 42(4):1241-1249. PubMed ID: 27904923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
    Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
    BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
    Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
    Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
    BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.